AI Article Synopsis
- The CD40/CD40L system plays a crucial role in immune cell co-stimulation and the soluble form of CD40L (sCD40L) is studied as a marker for inflammatory and autoimmune diseases, including Multiple Sclerosis (MS).
- In a study, researchers measured serum levels of sCD40L and 14 cytokines in MS patients treated with Glatiramer acetate or Interferon beta, finding a strong correlation between sCD40L and the anti-inflammatory cytokine IL-31 in healthy individuals.
- They observed significant reductions in both sCD40L and IL-31 levels, along with changes in gene expression, suggesting these markers may help in assessing MS progression and tailoring more
Article Abstract
The CD40/CD40L system is a binding key for co-stimulation of immune cells. Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases. Here we analyze serum concentrations of sCD40L, as well as 14 cytokines, in patients with Multiple Sclerosis (MS) treated with Glatiramer acetate or Interferon beta. In the healthy control group, we found in serum a highly positive correlation between sCD40L and Interleukin (IL)-31, an anti-inflammatory Th2 cytokine. Additionally, an important reduction in IL-31 and sCD40L serum levels, as well as a significant reduction in CD40 mRNA expression and complete depletion of CD40L mRNA, detected from peripheral blood cells, was found in treated patients with MS. Therefore, sCD40L and IL-31 must be taken into account as possible prognostic markers when analyzing the disease progress of MS in order to provide more personalized treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.imbio.2017.10.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!